Skip to main content
GutCited
Figure 14

Описание

Secondary endpoint analysis from the IBS-C trial, including measures of abdominal discomfort and transit time.

More Figures from This Paper

Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement.

Figure 6

Comparative analysis of individual IBS symptom domains across treatment groups, evaluating the differential effects of the inulin-choline-silymarin supplement.

chart
Symptom severity distribution at the initial evaluation, revealing that approximately half of the IBS-C patients presented with moderate symptoms while over 40% had severe manifestations.

Figure 7

Symptom severity distribution at the initial evaluation, revealing that approximately half of the IBS-C patients presented with moderate symptoms while over 40% had severe manifestations.

chart
Total IBS symptom scores measured at the 28-day assessment point, comparing outcomes between the supplemented and control diet groups in the crossover design.

Figure 8

Total IBS symptom scores measured at the 28-day assessment point, comparing outcomes between the supplemented and control diet groups in the crossover design.

chart
Analysis of gastrointestinal symptom domains in the IBS-C study at an intermediate time point, tracking changes in bloating, pain, and bowel habit parameters.

Figure 9

Analysis of gastrointestinal symptom domains in the IBS-C study at an intermediate time point, tracking changes in bloating, pain, and bowel habit parameters.

chart
Stool frequency and consistency measurements during the treatment phase, evaluating whether inulin-based supplementation improved bowel regularity in IBS-C patients.

Figure 10

Stool frequency and consistency measurements during the treatment phase, evaluating whether inulin-based supplementation improved bowel regularity in IBS-C patients.

chart
Quality of life assessment data from IBS-C patients, comparing self-reported well-being between supplementation and control periods.

Figure 11

Quality of life assessment data from IBS-C patients, comparing self-reported well-being between supplementation and control periods.

chart

Figure 14

Chart
537 × 446px · 17,8 КБ

Source Paper

Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study.

Journal of clinical medicine (2022)

PMID: 35456341

DOI: 10.3390/jcm11082248

Cite This Figure

![Figure 14: Secondary endpoint analysis from the IBS-C trial, including measures of abdominal discomfort and transit time.](https://pdfs.citedhealth.com/figures/35456341/171.png)

> Source: Oana-Bogdana Bărboi et al. "Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with ." *Journal of clinical medicine*, 2022. PMID: [35456341](https://pubmed.ncbi.nlm.nih.gov/35456341/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/35456341/171.png" alt="Secondary endpoint analysis from the IBS-C trial, including measures of abdominal discomfort and transit time." />
  <figcaption>Figure 14. Secondary endpoint analysis from the IBS-C trial, including measures of abdominal discomfort and transit time.<br>  Source: Oana-Bogdana Bărboi et al. "Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with ." <em>Journal of clinical medicine</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35456341/">35456341</a></figcaption>
</figure>

Связанные доказательства

B
Inulin для Chronic Constipation

Оценка B · 6 исследований